Cargando…

Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis

BACKGROUND: Recent studies have revealed the endocannabinoid system as a potential therapeutic target in the management of nonalcoholic fatty liver disease (NAFLD). Cannabis use is associated with reduced risk for NAFLD, we hypothesized that cannabis use would be associated with less liver-related c...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Catherine J, Weiss, Stanley H, Nasir, Umair M, Pyrsopoulos, Nikolaos T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701971/
https://www.ncbi.nlm.nih.gov/pubmed/33312424
http://dx.doi.org/10.4254/wjh.v12.i11.993
_version_ 1783616521559343104
author Choi, Catherine J
Weiss, Stanley H
Nasir, Umair M
Pyrsopoulos, Nikolaos T
author_facet Choi, Catherine J
Weiss, Stanley H
Nasir, Umair M
Pyrsopoulos, Nikolaos T
author_sort Choi, Catherine J
collection PubMed
description BACKGROUND: Recent studies have revealed the endocannabinoid system as a potential therapeutic target in the management of nonalcoholic fatty liver disease (NAFLD). Cannabis use is associated with reduced risk for NAFLD, we hypothesized that cannabis use would be associated with less liver-related clinical complications in patients with NAFLD. AIM: To assess the effects of cannabis use on liver-related clinical outcomes in hospitalized patients with NAFLD. METHODS: We performed a retrospective matched cohort study based on querying the 2014 National Inpatient Sample (NIS) for hospitalizations of adults with a diagnosis of NAFLD. The NIS database is publicly available and the largest all-payer inpatient database in the United States. The patients with cannabis use were selected as cases and those without cannabis were selected as controls. Case-control matching at a ratio of one case to two controls was performed based on sex, age, race, and comorbidities. The liver-related outcomes such as portal hypertension, ascites, varices and variceal bleeding, and cirrhosis were compared between the groups. RESULTS: A total of 49911 weighed hospitalizations with a diagnosis of NAFLD were identified. Of these, 3820 cases were selected as the cannabis group, and 7625 non-cannabis cases were matched as controls. Patients with cannabis use had a higher prevalence of ascites (4.5% vs 3.6%), with and without cannabis use, P = 0.03. The prevalence of portal hypertension (2.1% vs 2.2%), varices and variceal bleeding (1.3% vs 1.7%), and cirrhosis (3.7% vs 3.6%) was not different between the groups, with and without cannabis use, all P > 0.05. Hyperlipidemia, race/ethnicity other than White, Black, Asian, Pacific Islander or Native American, and higher comorbidity score were independent risk factors for ascites in the cannabis group. Among non-cannabis users, obesity and hyperlipidemia were independent protective factors against ascites while older age, Native American and higher comorbidity index were independent risk factors for ascites. CONCLUSION: Cannabis was associated with higher rates of ascites, but there was no statistical difference in the prevalence of portal hypertension, varices and variceal bleeding, and cirrhosis.
format Online
Article
Text
id pubmed-7701971
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-77019712020-12-10 Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis Choi, Catherine J Weiss, Stanley H Nasir, Umair M Pyrsopoulos, Nikolaos T World J Hepatol Retrospective Cohort Study BACKGROUND: Recent studies have revealed the endocannabinoid system as a potential therapeutic target in the management of nonalcoholic fatty liver disease (NAFLD). Cannabis use is associated with reduced risk for NAFLD, we hypothesized that cannabis use would be associated with less liver-related clinical complications in patients with NAFLD. AIM: To assess the effects of cannabis use on liver-related clinical outcomes in hospitalized patients with NAFLD. METHODS: We performed a retrospective matched cohort study based on querying the 2014 National Inpatient Sample (NIS) for hospitalizations of adults with a diagnosis of NAFLD. The NIS database is publicly available and the largest all-payer inpatient database in the United States. The patients with cannabis use were selected as cases and those without cannabis were selected as controls. Case-control matching at a ratio of one case to two controls was performed based on sex, age, race, and comorbidities. The liver-related outcomes such as portal hypertension, ascites, varices and variceal bleeding, and cirrhosis were compared between the groups. RESULTS: A total of 49911 weighed hospitalizations with a diagnosis of NAFLD were identified. Of these, 3820 cases were selected as the cannabis group, and 7625 non-cannabis cases were matched as controls. Patients with cannabis use had a higher prevalence of ascites (4.5% vs 3.6%), with and without cannabis use, P = 0.03. The prevalence of portal hypertension (2.1% vs 2.2%), varices and variceal bleeding (1.3% vs 1.7%), and cirrhosis (3.7% vs 3.6%) was not different between the groups, with and without cannabis use, all P > 0.05. Hyperlipidemia, race/ethnicity other than White, Black, Asian, Pacific Islander or Native American, and higher comorbidity score were independent risk factors for ascites in the cannabis group. Among non-cannabis users, obesity and hyperlipidemia were independent protective factors against ascites while older age, Native American and higher comorbidity index were independent risk factors for ascites. CONCLUSION: Cannabis was associated with higher rates of ascites, but there was no statistical difference in the prevalence of portal hypertension, varices and variceal bleeding, and cirrhosis. Baishideng Publishing Group Inc 2020-11-27 2020-11-27 /pmc/articles/PMC7701971/ /pubmed/33312424 http://dx.doi.org/10.4254/wjh.v12.i11.993 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Cohort Study
Choi, Catherine J
Weiss, Stanley H
Nasir, Umair M
Pyrsopoulos, Nikolaos T
Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
title Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
title_full Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
title_fullStr Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
title_full_unstemmed Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
title_short Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
title_sort cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: a nationwide analysis
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701971/
https://www.ncbi.nlm.nih.gov/pubmed/33312424
http://dx.doi.org/10.4254/wjh.v12.i11.993
work_keys_str_mv AT choicatherinej cannabisusehistoryisassociatedwithincreasedprevalenceofascitesamongpatientswithnonalcoholicfattyliverdiseaseanationwideanalysis
AT weissstanleyh cannabisusehistoryisassociatedwithincreasedprevalenceofascitesamongpatientswithnonalcoholicfattyliverdiseaseanationwideanalysis
AT nasirumairm cannabisusehistoryisassociatedwithincreasedprevalenceofascitesamongpatientswithnonalcoholicfattyliverdiseaseanationwideanalysis
AT pyrsopoulosnikolaost cannabisusehistoryisassociatedwithincreasedprevalenceofascitesamongpatientswithnonalcoholicfattyliverdiseaseanationwideanalysis